Five European Biotech Stocks Face Pivotal Trial Results in 2026

Five European Biotech Stocks Face Pivotal Trial Results in 2026



Five European Biotech Stocks Face Pivotal Trial Results in 2026
It’s been a big year for European biotech stocks: Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro Stoxx 50 Index and smaller names including Valneva SE and Inventiva also had impressive rallies.


www.bloomberg.com
#European #Biotech #Stocks #Face #Pivotal #Trial #Results

Share: X · Facebook · LinkedIn

Leave a Reply

Your email address will not be published. Required fields are marked *